The company utilizes a transgenic animal model to efficiently discover and develop therapeutic antibodies for human use. This approach enables clients to access diverse and high-quality antibody drug candidates in reduced timelines, addressing the need for faster and more effective therapeutic solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody discovery methods can be time-consuming and may not always yield therapeutic candidates with optimal diversity and developability. This can delay the development of new medicines and limit the availability of effective treatments for various diseases.
Solution
AlivaMab Biologics offers an efficient platform for discovering and developing therapeutic antibodies using a transgenic animal model. This technology enables the generation of diverse panels of high-quality antibody drug candidates in accelerated timelines. By leveraging this approach, clients can access promising therapeutic solutions more rapidly, increasing the likelihood of successful development programs and ultimately bringing better medicines to patients faster.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies seeking to discover and develop novel antibody therapeutics for human diseases.
Features
- Transgenic animal model for generating human therapeutic antibodies
- Efficient discovery and development process, reducing timelines
- Generation of diverse panels of antibody drug candidates
- Focus on developability to improve the likelihood of successful clinical translation